Cartesian Therapeutics (RNAC) Other Non Operating Income: 2015-2025
Historic Other Non Operating Income for Cartesian Therapeutics (RNAC) over the last 10 years, with Jun 2025 value amounting to -$5,000.
- Cartesian Therapeutics' Other Non Operating Income fell 101.71% to -$5,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $93,000, marking a year-over-year decrease of 90.62%. This contributed to the annual value of $606,000 for FY2024, which is 12.30% down from last year.
- Per Cartesian Therapeutics' latest filing, its Other Non Operating Income stood at -$5,000 for Q2 2025, which was up 98.87% from -$444,000 recorded in Q4 2024.
- In the past 5 years, Cartesian Therapeutics' Other Non Operating Income registered a high of $508,000 during Q1 2024, and its lowest value of -$444,000 during Q4 2024.
- Over the past 3 years, Cartesian Therapeutics' median Other Non Operating Income value was $250,000 (recorded in 2024), while the average stood at $143,556.
- Examining YoY changes over the last 5 years, Cartesian Therapeutics' Other Non Operating Income showed a top increase of 2,100.00% in 2022 and a maximum decrease of 642.86% in 2022.
- Cartesian Therapeutics' Other Non Operating Income (Quarterly) stood at $9,000 in 2021, then spiked by 66.67% to $175,000 in 2022, then slumped by 135.43% to -$62,000 in 2023, then slumped by 616.13% to -$444,000 in 2024, then slumped by 101.71% to -$5,000 in 2025.
- Its Other Non Operating Income was -$5,000 in Q2 2025, compared to -$444,000 in Q4 2024 and $250,000 in Q3 2024.